Published in Hum Mol Genet on December 01, 1994
Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet (2014) 5.74
Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A (1996) 5.69
Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc Natl Acad Sci U S A (2001) 4.60
Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci U S A (1996) 3.88
Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol Cell Biol (1998) 3.30
The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol (1997) 2.76
von Hippel-Lindau disease: a clinical and scientific review. Eur J Hum Genet (2011) 2.45
The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res (2010) 2.03
HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Invest (2003) 1.99
Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. Cancer Cell (2003) 1.85
Influence of the RNA-binding protein HuR in pVHL-regulated p53 expression in renal carcinoma cells. Mol Cell Biol (2003) 1.83
The ubiquitin system, disease, and drug discovery. BMC Biochem (2008) 1.73
Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density. Proc Natl Acad Sci U S A (1996) 1.66
The inducible elongin A elongation activation domain: structure, function and interaction with the elongin BC complex. EMBO J (1996) 1.62
Alterations in VHL as potential biomarkers in renal-cell carcinoma. Nat Rev Clin Oncol (2010) 1.55
Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors. Am J Hum Genet (1997) 1.54
Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene (2010) 1.52
Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features. Am J Pathol (1996) 1.52
Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma. Clin Cancer Res (2009) 1.49
Decreased growth of Vhl-/- fibrosarcomas is associated with elevated levels of cyclin kinase inhibitors p21 and p27. Mol Cell Biol (2005) 1.47
Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study. BMC Cancer (2005) 1.41
Oxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor protein. Mol Cell Biol (2002) 1.38
Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein. Mol Cell Biol (1999) 1.30
VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. Curr Oncol Rep (2009) 1.25
The VHL protein recruits a novel KRAB-A domain protein to repress HIF-1alpha transcriptional activity. EMBO J (2003) 1.24
Functional epigenomics approach to identify methylated candidate tumour suppressor genes in renal cell carcinoma. Br J Cancer (2008) 1.23
Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas. J Med Genet (1995) 1.17
Identification of the RNA polymerase II subunit hsRPB7 as a novel target of the von Hippel-Lindau protein. EMBO J (2003) 1.12
Software and database for the analysis of mutations in the VHL gene. Nucleic Acids Res (1998) 1.12
Analysis of the TSC1 and TSC2 genes in sporadic renal cell carcinomas. Br J Cancer (2001) 1.11
SLIT2 promoter methylation analysis in neuroblastoma, Wilms' tumour and renal cell carcinoma. Br J Cancer (2004) 1.10
Nucleostemin mRNA is expressed in both normal and malignant renal tissues. Br J Cancer (2006) 1.07
An analysis of phenotypic variation in the familial cancer syndrome von Hippel-Lindau disease: evidence for modifier effects. Am J Hum Genet (1998) 1.07
Genome-wide CpG island methylation analysis implicates novel genes in the pathogenesis of renal cell carcinoma. Epigenetics (2012) 1.04
The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy. Kidney Int (2009) 1.03
Role of chromosome 3p12-p21 tumour suppressor genes in clear cell renal cell carcinoma: analysis of VHL dependent and VHL independent pathways of tumorigenesis. Mol Pathol (2000) 1.02
Allelic deletion and mutation of the von Hippel-Lindau (VHL) tumor suppressor gene in pancreatic microcystic adenomas. Am J Pathol (1997) 1.01
Analysis of germline variants in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF in familial and sporadic renal cell carcinoma. PLoS One (2009) 1.00
Methylation profiling and evaluation of demethylating therapy in renal cell carcinoma. Clin Epigenetics (2013) 0.98
Molecular genetic analysis of FIH-1, FH, and SDHB candidate tumour suppressor genes in renal cell carcinoma. J Clin Pathol (2004) 0.97
The von Hippel-Lindau gene: turning discovery into therapy. Cancer (2008) 0.97
VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo. Oncogene (2009) 0.96
Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma. Gynecol Oncol (2007) 0.96
Investigation of the role of SDHB inactivation in sporadic phaeochromocytoma and neuroblastoma. Br J Cancer (2004) 0.96
Mutation analysis of HIF prolyl hydroxylases (PHD/EGLN) in individuals with features of phaeochromocytoma and renal cell carcinoma susceptibility. Endocr Relat Cancer (2010) 0.95
The molecular basis of von Hippel-Lindau disease. Mol Med (1997) 0.95
Chromosome 3p allele loss in early invasive breast cancer: detailed mapping and association with clinicopathological features. Mol Pathol (2001) 0.92
Differential expression of prognostic proteomic markers in primary tumour, venous tumour thrombus and metastatic renal cell cancer tissue and correlation with patient outcome. PLoS One (2013) 0.91
An alternative route for multistep tumorigenesis in a novel case of hereditary renal cell cancer and a t(2;3)(q35;q21) chromosome translocation. Am J Hum Genet (1998) 0.89
Transcription syndromes and the role of RNA polymerase II general transcription factors in human disease. J Clin Invest (1996) 0.89
Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes. J Med Genet (2000) 0.89
The role of angiogenesis in prostate and other urologic cancers: a review. CMAJ (2001) 0.88
Tumor-specific hypermethylation of epigenetic biomarkers, including SFRP1, predicts for poorer survival in patients from the TCGA Kidney Renal Clear Cell Carcinoma (KIRC) project. PLoS One (2014) 0.88
Differences in regulation of tight junctions and cell morphology between VHL mutations from disease subtypes. BMC Cancer (2009) 0.87
Future directions in renal cell carcinoma: 2011 and beyond. Hematol Oncol Clin North Am (2011) 0.87
Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy. Nat Rev Urol (2009) 0.87
A multinodular goiter as the initial presentation of a renal cell carcinoma harbouring a novel VHL mutation. BMC Endocr Disord (2006) 0.85
Somatic deletion of the 5' ends of both the COL4A5 and COL4A6 genes in a sporadic leiomyoma of the esophagus. Am J Pathol (1998) 0.84
The Role of Hypoxia and Cancer Stem Cells in Renal Cell Carcinoma Pathogenesis. Stem Cell Rev (2015) 0.84
An integrated computational approach can classify VHL missense mutations according to risk of clear cell renal carcinoma. Hum Mol Genet (2014) 0.83
Genetic and functional analysis of the von Hippel-Lindau (VHL) tumour suppressor gene promoter. J Med Genet (2002) 0.82
Hepatocyte growth factor-stimulated renal tubular mitogenesis: effects on expression of c-myc, c-fos, c-met, VEGF and the VHL tumour-suppressor and related genes. Br J Cancer (1998) 0.82
Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions. Ther Adv Med Oncol (2010) 0.81
Matriptase and MET are prominently expressed at the site of bone metastasis in renal cell carcinoma: immunohistochemical analysis. Hum Cell (2014) 0.80
PANDA: pathway and annotation explorer for visualizing and interpreting gene-centric data. PeerJ (2015) 0.79
Genetic changes in the origin and development of renal cell carcinoma (RCC). Pflugers Arch (1996) 0.79
UBE2QL1 is disrupted by a constitutional translocation associated with renal tumor predisposition and is a novel candidate renal tumor suppressor gene. Hum Mutat (2013) 0.78
Functional evaluation of the apoptosome in renal cell carcinoma. Br J Cancer (2003) 0.78
Two single nucleotide polymorphisms in the von Hippel-Lindau tumor suppressor gene in Taiwanese with renal cell carcinoma. BMC Res Notes (2014) 0.77
Renal cell carcinoma with mixed features of papillary and clear cell cytomorphology: a fluorescent in situ hybridization study. Virchows Arch (2009) 0.77
Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines. J Cancer Res Clin Oncol (2012) 0.77
Renal Cell Carcinoma Metastatic to the Thyroid Gland: A Comparative Molecular Study Between the Primary and the Metastatic Tumor. Endocr Pathol (1998) 0.76
Evidence for aldosterone-dependent growth of renal cell carcinoma. Int J Exp Pathol (2014) 0.76
Integrative analysis of protein-coding and non-coding RNAs identifies clinically relevant subtypes of clear cell renal cell carcinoma. Oncotarget (2016) 0.75
Immune and genetic therapies for advanced renal cell carcinoma. Rev Urol (2000) 0.75
State-of-the-art treatment of metastatic renal cell carcinoma. Curr Oncol (2009) 0.75
Structure, function and regulation of jade family PHD finger 1 (JADE1). Gene (2016) 0.75
The interpretation of protein structures: estimation of static accessibility. J Mol Biol (1971) 40.24
Areas, volumes, packing and protein structure. Annu Rev Biophys Bioeng (1977) 16.38
Tertiary templates for proteins. Use of packing criteria in the enumeration of allowed sequences for different structural classes. J Mol Biol (1987) 10.85
The chemical shift index: a fast and simple method for the assignment of protein secondary structure through NMR spectroscopy. Biochemistry (1992) 9.40
Relationship between nuclear magnetic resonance chemical shift and protein secondary structure. J Mol Biol (1991) 8.38
Multicolor spectral karyotyping of human chromosomes. Science (1996) 7.65
The interpretation of protein structures: total volume, group volume distributions and packing density. J Mol Biol (1974) 5.39
The Heidelberg classification of renal cell tumours. J Pathol (1997) 5.36
A voltage-gated ion channel model inferred from the crystal structure of alamethicin at 1.5-A resolution. Nature (1982) 4.92
Microsatellite evolution--evidence for directionality and variation in rate between species. Nat Genet (1995) 4.77
Clinical features and natural history of von Hippel-Lindau disease. Q J Med (1990) 4.71
Confirmation of linkage of the loci for myotonic dystrophy and ABH secretion. J Med Genet (1971) 4.70
Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res (1998) 4.33
Structural determinants of peptide-binding orientation and of sequence specificity in SH3 domains. Nature (1994) 4.29
Chemical cross-linking: reagents and problems in studies of membrane structure. Annu Rev Biochem (1977) 4.19
Analysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy. Nature (1986) 4.13
DPC4 gene in various tumor types. Cancer Res (1996) 3.74
Von Hippel-Lindau disease: a genetic study. J Med Genet (1991) 3.61
The matching of physical models to three-dimensional electron-density maps: a simple optical device. J Mol Biol (1968) 3.30
Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature (1984) 3.24
Glutaraldehyde as a protein cross-linkage reagent. J Mol Biol (1968) 3.18
High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res (1996) 3.18
Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res (1997) 3.17
The candidate Wilms' tumour gene is involved in genitourinary development. Nature (1990) 3.13
A gene in the chromosomal region 3p21 with greatly reduced expression in lung cancer is similar to the gene for ubiquitin-activating enzyme. Proc Natl Acad Sci U S A (1993) 3.09
Cloned DNA probes regionally mapped to human chromosome 21 and their use in determining the origin of nondisjunction. Nucleic Acids Res (1985) 3.09
Localization of human immunoglobulin kappa light chain variable region genes to the short arm of chromosome 2 by in situ hybridization. Proc Natl Acad Sci U S A (1982) 3.07
Cytogenetic analysis by chromosome painting using DOP-PCR amplified flow-sorted chromosomes. Genes Chromosomes Cancer (1992) 3.03
Packing of alpha-helices: geometrical constraints and contact areas. J Mol Biol (1978) 2.95
Use of the avidin-biotin complex for specific staining of biological membranes in electron microscopy. Proc Natl Acad Sci U S A (1974) 2.91
Multicolour spectral karyotyping of mouse chromosomes. Nat Genet (1996) 2.90
Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat (1996) 2.80
The three-dimensional structure of ribonuclease-S. Interpretation of an electron density map at a nominal resolution of 2 A. J Biol Chem (1970) 2.77
X-Y chromosomal interchange in the aetiology of true hermaphroditism and of XX Klinefelter's syndrome. Lancet (1966) 2.68
Cystic fibrosis in the mouse by targeted insertional mutagenesis. Nature (1992) 2.66
An approach to nearest neighbor analysis of membrane proteins. Application to the human erythrocyte membrane of a method employing cleavable cross-linkages. J Biol Chem (1974) 2.53
Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum Mol Genet (1994) 2.52
1H-15N heteronuclear NMR studies of Escherichia coli thioredoxin in samples isotopically labeled by residue type. Biochemistry (1985) 2.39
Familial gastric cancer: overview and guidelines for management. J Med Genet (1999) 2.38
Isolated ductus arteriosus aneurysm in the fetus and infant: a multi-institutional experience. J Am Coll Cardiol (2000) 2.36
The structure of ribonuclease-S at 3.5 A resolution. J Biol Chem (1967) 2.33
Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer (1998) 2.27
The role of microRNAs in normal hematopoiesis and hematopoietic malignancies. Leukemia (2006) 2.21
Cardiovascular, skeletal, and renal defects in mice with a targeted disruption of the Pkd1 gene. Proc Natl Acad Sci U S A (2001) 2.19
Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science (1994) 2.16
A selective difference between human Y-chromosomal DNA haplotypes. Curr Biol (1999) 2.14
Hypernatraemia: why bother weighing breast fed babies? Arch Dis Child Fetal Neonatal Ed (2001) 2.13
The HA2 subunit of influenza hemagglutinin inserts into the target membrane prior to fusion. J Biol Chem (1991) 2.07
Construction of new ligand binding sites in proteins of known structure. I. Computer-aided modeling of sites with pre-defined geometry. J Mol Biol (1991) 2.05
Rapid determination of sequences flanking microsatellites. Nucleic Acids Res (1991) 2.04
A 10-megabase physical map of human Xp21, including the Duchenne muscular dystrophy gene. Genomics (1988) 2.04
Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency. Hum Mol Genet (2003) 2.04
Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin's lymphoma. Lancet (2005) 2.03
An experimental procedure for increasing the structural resolution of chemical hydrogen-exchange measurements on proteins: application to ribonuclease S peptide. J Mol Biol (1979) 1.99
Metabolic evidence that deficiencies of vitamin B-12 (cobalamin), folate, and vitamin B-6 occur commonly in elderly people. Am J Clin Nutr (1993) 1.98
Maternal age specific rates for chromosome aberrations and factors influencing them: report of a collaborative european study on 52 965 amniocenteses. Prenat Diagn (1984) 1.97
Crystal structure of hen egg-white lysozyme at a hydrostatic pressure of 1000 atmospheres. J Mol Biol (1987) 1.97
Genetic evidence that a Y-linked gene in man is homologous to a gene on the X chromosome. Nature (1983) 1.94
Human centromeric DNAs. Hum Genet (1997) 1.94
Characterization of colicin Ia and colicin Ib. Purification and some physical properties. J Biol Chem (1970) 1.93
Localization of DNA sequences required for human centromere function through an analysis of rearranged Y chromosomes. Nat Genet (1993) 1.92
Heat capacity changes for protein-peptide interactions in the ribonuclease S system. Biochemistry (1992) 1.91
Avoidance of anencephalic and spina bifida births by maternal serum-alphafetoprotein screening. Lancet (1978) 1.90
The reduction of anencephalic and spina bifida births by maternal serum alphafetoprotein screening. Br Med Bull (1983) 1.89
Principles and applications of nanofluidic transport. Nat Nanotechnol (2009) 1.88
Reverse chromosome painting: a method for the rapid analysis of aberrant chromosomes in clinical cytogenetics. J Med Genet (1992) 1.85
Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia, type II. JAMA (1995) 1.83
NMR sequential assignment of Escherichia coli thioredoxin utilizing random fractional deuteriation. Biochemistry (1988) 1.83
Recommended biocontainment features for research and diagnostic facilities where animal pathogens are used. First International Veterinary Biosafety Workshop. Rev Sci Tech (1995) 1.81
A comparative study of karyotypes of muntjacs by chromosome painting. Chromosoma (1995) 1.81
A complete comparative chromosome map for the dog, red fox, and human and its integration with canine genetic maps. Genomics (1999) 1.79
Reciprocal chromosome painting among human, aardvark, and elephant (superorder Afrotheria) reveals the likely eutherian ancestral karyotype. Proc Natl Acad Sci U S A (2003) 1.79
Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations. J Med Genet (1996) 1.76
Protein folding: evaluation of some simple rules for the assembly of helices into tertiary structures with myoglobin as an example. J Mol Biol (1979) 1.72
Gender verification in the Olympics. JAMA (2000) 1.72
Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors. Cancer Res (1998) 1.71
Mutational bias provides a model for the evolution of Huntington's disease and predicts a general increase in disease prevalence. Nat Genet (1994) 1.71
Regulation of pri-microRNA BIC transcription and processing in Burkitt lymphoma. Oncogene (2006) 1.69
Mishaps during transport from the intensive care unit. Crit Care Med (1990) 1.67
High-resolution analysis of human peripheral lymphocyte chromosomes by flow cytometry. Proc Natl Acad Sci U S A (1981) 1.65
Calculation of molecular volumes and areas for structures of known geometry. Methods Enzymol (1985) 1.64
The impact of pre-operative education on recovery following coronary artery bypass surgery. A randomized controlled clinical trial. Eur Heart J (2002) 1.64
Genetic divergence in the clonal evolution of breast cancer. Cancer Res (1996) 1.63
Localisation of the human ABO: Np-1: AK-1 linkage group by regional assignment of AK-1 to 9q34. Hum Genet (1976) 1.63
Deletion of a DNA sequence in eight of nine families with X-linked ichthyosis (steroid sulphatase deficiency). Nucleic Acids Res (1987) 1.62
Assignment of the gene for dyskeratosis congenita to Xq28. Hum Genet (1986) 1.62
Anion binding and pH-dependent electrostatic effects in ribonuclease. Biochemistry (1982) 1.62
Electroporation of cells in microfluidic devices: a review. Anal Bioanal Chem (2006) 1.61